Roscovitine-treated HeLa cells finalize autophagy later than apoptosis by downregulating Bcl‑2

Coker‑Gurkan,Ajda; Arisan,Elif  Damla; Obakan,Pinar; Ozfiliz,Pelin; Kose,Betsi; Bickici,Guven; Palavan‑Unsal,Narcin

doi:10.3892/mmr.2014.2902

Roscovitine-treated HeLa cells finalize autophagy later than apoptosis by downregulating Bcl‑2

Authors:
- Ajda Coker‑Gurkan
- Elif Damla Arisan
- Pinar Obakan
- Pelin Ozfiliz
- Betsi Kose
- Guven Bickici
- Narcin Palavan‑Unsal
View Affiliations

Affiliations: Department of Molecular Biology and Genetics, Istanbul Kultur University, Istanbul 34156, Turkey
Published online on: November 7, 2014 https://doi.org/10.3892/mmr.2014.2902
Pages: 1968-1974

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The cell cycle is tightly regulated by the family of cyclin-dependent kinases (CDKs). CDKs act as regulatory factors on serine and threonine residues by phosphorylating their substrates and cyclins. CDK‑targeting drugs have previously demonstrated promising effects as cancer therapeutics both in vitro and in vivo. Roscovitine, a purine‑derivative and specific CDK inhibitor, has been demonstrated to arrest the cell cycle and induce apoptosis in a number of different cancer cell lines, including HeLa cervical cancer cells. In the present study, roscovitine was able to decrease both the cell viability and cell survival as well as induce apoptosis in a dose‑dependent manner in HeLa cells by modulating the mitochondrial membrane potential. The decrease of anti‑apoptotic B-cell lymphoma 2 (Bcl‑2) and Bcl-2 extra large protein expression was accompanied by the increase in pro‑apoptotic Bcl-2-associated X protein and P53-upregulated modulator of apoptosis expression. The marked decrease in Bcl‑2 following exposure to roscovitine (20 µM) for 48 h prompted us to determine the autophagic regulation. The outcome revealed that roscovitine triggered Beclin‑1 downregulation and microtubule-associated light chain 3 cleavage starting from 12 h of incubation. Another biomarker of autophagy, p62, a crucial protein for autophagic vacuole formation, was diminished following 48 h. In addition, monodansyl cadaverin staining of autophagosomes also confirmed the autophagic regulation by roscovitine treatment. The expression levels of different Bcl‑2 family members determined whether apoptosis or autophagy were induced following incubation with roscovitine for different time periods. Downregulation of pro‑apoptotic Bcl‑2 family members indicated induction of apoptosis, while the downregulation of anti‑apoptotic Bcl‑2 family members rapidly induced autophagosome formation in HeLa cells.

View Figures

View References

1	Wesierska-Gadek J, Gueorguieva M, Wojciechowski J and Horky M: Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine. Pol J Pharmacol. 56:635–641. 2004.PubMed/NCBI
2	Zhang T, Jiang T, Zhang F, et al: Involvement of p21Waf1/Cip1 cleavage during roscovitine-induced apoptosis in non-small cell lung cancer cells. Oncol Rep. 23:239–245. PubMed/NCBI
3	Wesierska-Gadek J, Wandl S, Kramer MP, et al: roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells. J Cell Biochem. 105:1161–1171. 2008. View Article : Google Scholar : PubMed/NCBI
4	Arisan ED, Coker A and Palavan-Ünsal N: Polyamine depletion enhances the roscovitine-induced apoptosis through the activation of mitochondria in HCT116 colon carcinoma cells. Amino Acids. 42:655–665. 2012. View Article : Google Scholar
5	Appleyard MV, O’Neill MA, Murray KE, et al: Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer. 124:465–472. 2009. View Article : Google Scholar
6	Kondo Y, Kanzawa T, Sawaya R and Kondo S: The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
7	Gozuacik D and Kimchi A: Autophagy and cell death. Curr Top Dev Biol. 78:217–245. 2007. View Article : Google Scholar : PubMed/NCBI
8	Maiuri MC, Zalckvar E, Kimchi A and Kroemer G: Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol. 8:741–752. 2007. View Article : Google Scholar : PubMed/NCBI
9	Wang J: Beclin 1 bridges autophagy, apoptosis and differentiation. Autophagy. 4:947–948. 2008. View Article : Google Scholar : PubMed/NCBI
10	Ku B, Woo JS, Liang C, et al: An insight into the mechanistic role of Beclin 1 and its inhibition by prosurvival Bcl-2 family proteins. Autophagy. 4:519–520. 2008. View Article : Google Scholar : PubMed/NCBI
11	Maiuri MC, Criollo A, Tasdemir E, et al: BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy. 3:374–376. 2007. View Article : Google Scholar : PubMed/NCBI
12	Zalckvar E, Berissi H, Eisenstein M and Kimchi A: Phosphorylation of Beclin 1 by DAP-kinase promotes autophagy by weakening its interactions with Bcl-2 and Bcl-XL. Autophagy. 5:720–722. 2009. View Article : Google Scholar : PubMed/NCBI
13	Anorlu RI: What is the significance of the HPV epidemic? Can J Urol. 15:3860–3865. 2008.PubMed/NCBI
14	Weinstein LC, Buchanan EM, Hillson C and Chambers CV: Screening and prevention: cervical cancer. Prim Care. 36:559–574. 2009. View Article : Google Scholar : PubMed/NCBI
15	Singh KC, Agarwal A, Agarwal S, et al: ‘Quick course’ neoadjuvant chemotherapy with cisplatin, bleomycin and vincristine in advanced cervical cancer. Gynecol Obstet Invest. 58:109–113. 2004. View Article : Google Scholar
16	van Luijk IF, Coens C, van der Burg ME, et al: Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix. Ann Oncol. 18:275–281. 2007. View Article : Google Scholar
17	Benson C, White J, De Bono J, et al: A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer. 96:29–37. 2007. View Article : Google Scholar
18	Sherr CJ: Cancer cell cycles. Science. 274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
19	Guzi T: CYC-202 Cyclacel. Curr Opin Investig Drugs. 5:1311–1318. 2004.
20	Coley HM, Shotton CF and Thomas H: Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines. Anticancer Res. 27:273–278. 2007.PubMed/NCBI
21	Dey A, Wong ET, Cheok CF, Tergaonkar V and Lane DP: R-roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ. 15:263–273. 2008. View Article : Google Scholar
22	Duffin R, Leitch AE, Sheldrake TA, et al: The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1. FEBS Lett. 583:2540–2546. 2009. View Article : Google Scholar : PubMed/NCBI
23	Goodyear S and Sharma MC: roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5. Exp Mol Pathol. 82:25–32. 2007. View Article : Google Scholar
24	Maurer M, Komina O and Wesierska-Gadek J: roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells. Ann NY Acad Sci. 1171:250–256. 2009. View Article : Google Scholar : PubMed/NCBI
25	Mitchell C, Park MA, Zhang G, et al: Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Mol Cancer Ther. 6:3101–3112. 2007. View Article : Google Scholar : PubMed/NCBI
26	Nair BC, Vallabhaneni S, Tekmal RR and Vadlamudi RK: roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Res. 13:R802011. View Article : Google Scholar : PubMed/NCBI
27	Ribas J, Boix J and Meijer L: (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. Exp Cell Res. 312:2394–2400. 2006. View Article : Google Scholar : PubMed/NCBI
28	Zolnierczyk JD, Bloński JZ, Robak T, Kiliańska ZM and Wesierska-Gadek J: roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide. Ann NY Acad Sci. 1171:124–131. 2009. View Article : Google Scholar : PubMed/NCBI
29	Wesierska-Gadek J, Gueorguieva M and Horky M: roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol Cancer Ther. 4:113–124. 2005.PubMed/NCBI
30	Lambert LA, Qiao N, Hunt KK, et al: Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res. 68:7966–7974. 2008. View Article : Google Scholar : PubMed/NCBI
31	Houel-Renault L, Philippe L, Piquemal M and Ciapa B: Autophagy is used as a survival program in unfertilized sea urchin eggs that are destined to die by apoptosis after inactivation of MAPK1/3 (ERK2/1). Autophagy. 9:1527–1539. 2013. View Article : Google Scholar : PubMed/NCBI
32	Sinha S and Levine B: The autophagy effector Beclin 1: a novel BH3-only protein. Oncogene. 27(Suppl 1): S137–S148. 2008. View Article : Google Scholar
33	Wei Y, Sinha S and Levine B: Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation. Autophagy. 4:949–951. 2008. View Article : Google Scholar : PubMed/NCBI
34	Zalckvar E, Berissi H, Mizrachy L, et al: DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-XL and induction of autophagy. EMBO Rep. 10:285–292. 2009. View Article : Google Scholar : PubMed/NCBI
35	Kabeya Y, Mizushima N, Ueno T, et al: LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. Embo J. 19:5720–5728. 2000. View Article : Google Scholar : PubMed/NCBI